Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy

Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS spectrums Ročník 28; číslo 4; s. 416 - 426
Hlavní autoři: Dodd, Seetal, Norman, Trevor R., Eyre, Harris A., Stahl, Stephen M., Phillips, Arnie, Carvalho, André F., Berk, Michael
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York, USA Cambridge University Press 01.08.2023
Témata:
Drug dosages
Hallucinogens - adverse effects
Hallucinogens - pharmacology
Hallucinogens - therapeutic use
Humans
Mental Disorders - drug therapy
Metabolism
Metabolites
Mushrooms
Oral administration
Pharmacokinetics
Pharmacology
Plasma
Psilocybin - adverse effects
Psilocybin - analogs & derivatives
Psilocybin - pharmacology
Psilocybin - therapeutic use
Psychedelic drugs
Review
treatment
anxiety
neuroscience
safety
Psilocybin
psychiatry
depression
adverse events
posttraumatic stress disorder
ISSN:1092-8529, 2165-6509
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.
AbstractList Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.
Author Norman, Trevor R.
Carvalho, André F.
Berk, Michael
Phillips, Arnie
Dodd, Seetal
Stahl, Stephen M.
Eyre, Harris A.
Author_xml – sequence: 1
  givenname: Seetal
  orcidid: 0000-0002-7918-4636
  surname: Dodd
  fullname: Dodd, Seetal
  email: seetald@barwonhealth.org.au
  organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia
– sequence: 2
  givenname: Trevor R.
  surname: Norman
  fullname: Norman, Trevor R.
  organization: Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia
– sequence: 3
  givenname: Harris A.
  surname: Eyre
  fullname: Eyre, Harris A.
  organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia
– sequence: 4
  givenname: Stephen M.
  surname: Stahl
  fullname: Stahl, Stephen M.
  organization: 2 Department of Psychiatry, University of California San Diego, San Diego, CA, USA
– sequence: 5
  givenname: Arnie
  surname: Phillips
  fullname: Phillips, Arnie
  organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia
– sequence: 6
  givenname: André F.
  orcidid: 0000-0002-2500-5671
  surname: Carvalho
  fullname: Carvalho, André F.
  organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia
– sequence: 7
  givenname: Michael
  surname: Berk
  fullname: Berk, Michael
  organization: IMPACT – The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35811423$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtr3DAQgEVISHaT_oBcgiGXHuJGD1uScwtL0xYWkpK9m7E83ijY1kayW_zvq2W3LWxpYGAO833DPObkuHc9EnLJ6CdGmbp9ZrTgOucF55RSrfURmXEm81TmtDgms2053dbPyDyEV0ozobQ4JWci14xlXMzI96dgW2emyvZJjB5H7zZhMi8WBj_dJZB4_GHxZ-KaxA4h2byA78C41q2nmyRAg0PM0NcJNo01YKYLctJAG_DDPp-T1cPn1eJrunz88m1xv0xNxuSQ1lSbHJUEmVWCQa2wUQqVqUTFtZC0RiikKLSKOzQcNK_yuFnNTMWKTDNxTj7u2m68exsxDGVng8G2hR7dGEoutaZaCi4ien2AvrrR93G4kutMFTqLJ4rU1Z4aqw7rcuNtB34qf98qAmwHGO9C8Nj8QRgtt_8o__lHdNSBY-wAg3X94MG275pib0JXeVuv8e_U_7d-AefKm1o
CitedBy_id crossref_primary_10_1080_00207144_2025_2501964
crossref_primary_10_1007_s11469_025_01489_z
crossref_primary_10_1016_j_tips_2023_12_007
crossref_primary_10_1016_j_foodchem_2025_145719
crossref_primary_10_1038_s41380_023_02312_8
crossref_primary_10_3390_ph18071009
crossref_primary_10_1556_2054_2025_00464
crossref_primary_10_3390_pharmaceutics17040411
crossref_primary_10_1177_02698811241286771
crossref_primary_10_1080_14728214_2025_2488786
crossref_primary_10_1055_a_2529_7029
crossref_primary_10_1080_02791072_2024_2399128
crossref_primary_10_3389_fpsyt_2023_1278823
crossref_primary_10_1111_bph_17420
crossref_primary_10_1080_03007995_2024_2396536
crossref_primary_10_1080_14737175_2024_2445016
crossref_primary_10_1111_fcp_70038
crossref_primary_10_1177_02698811231179800
crossref_primary_10_3389_fpsyt_2023_1178529
crossref_primary_10_1007_s40266_025_01221_5
crossref_primary_10_3390_brainsci14080829
crossref_primary_10_37349_en_2025_1006105
crossref_primary_10_1177_20451253251372449
crossref_primary_10_1186_s40337_024_01005_z
crossref_primary_10_2147_NDT_S500337
Cites_doi 10.1007/s12231-011-9152-5
10.1248/bpb.b14-00315
10.1038/mp.2014.24
10.1523/JNEUROSCI.1659-20.2020
10.1111/j.1360-0443.2004.00744.x
10.1098/rsif.2014.0873
10.1038/s41386-020-0694-z
10.1177/0269881108094300
10.1046/j.1528-1157.2002.043s2028.x
10.1097/FBP.0000000000000394
10.1371/journal.pone.0009019
10.1016/S0893-133X(96)00246-1
10.1056/NEJMoa2032994
10.1111/1556-4029.13982
10.1038/s41386-019-0324-9
10.1021/acschemneuro.9b00493
10.3389/fphar.2021.640241
10.7554/eLife.62878
10.1176/appi.ajp.2019.19010035
10.1523/JNEUROSCI.2063-13.2013
10.1001/jamapsychiatry.2020.3285
10.1177/26331055211033847
10.1021/jm000339w
10.1016/j.jchromb.2020.122486
10.1371/journal.pone.0063972
10.1097/00001756-199812010-00024
10.1097/00008877-199811000-00011
10.1016/bs.pbr.2018.08.003
10.1016/j.celrep.2018.05.022
10.1038/sj.npp.1300505
10.1016/j.neuroimage.2020.116980
10.1080/02791072.1998.10399715
10.1007/s00213-017-4771-x
10.1111/acps.12275
10.1080/02791072.2019.1593559
10.1073/pnas.0708862105
10.1001/archgenpsychiatry.2010.116
10.1016/0006-2952(62)90050-3
10.1016/j.biopsych.2012.04.005
10.1016/S0893-133X(98)00089-X
10.1016/j.pharmthera.2018.11.010
10.3389/fpsyt.2021.727117
10.1016/j.neuron.2007.01.008
10.1007/s00221-013-3579-0
10.1021/acschemneuro.8b00186
10.1016/j.neuropharm.2017.12.041
10.1007/s13311-017-0542-y
10.1016/S0893-133X(98)00108-0
10.3389/fpsyt.2017.00240
10.1038/s41398-021-01603-4
10.1016/j.euroneuro.2013.12.006
10.1007/s12231-008-9033-8
10.1080/03602532.2016.1278228
10.1016/j.euroneuro.2016.05.001
10.1093/ijnp/pyx047
10.1080/10550887.2019.1673655
10.1073/pnas.1119598109
10.1016/S0031-6865(97)00014-9
10.1016/j.psychres.2020.112749
10.1016/S0731-7085(02)00278-9
10.1111/j.1476-5381.2011.01516.x
10.1002/hlca.19590420518
10.1177/0269881114565144
10.1016/bs.pbr.2018.09.013
10.1016/j.jchromb.2011.07.003
10.1038/nrn2884
10.1016/j.brainresbull.2016.04.016
10.1016/j.neuropharm.2019.107933
10.1080/1355621021000005937
10.1007/s00213-014-3557-7
10.1177/0269881110382466
10.1016/j.neuropharm.2018.05.012
10.1007/s40262-017-0540-6
10.1007/BF02160424
10.1177/0269881116675513
10.1038/s41598-017-13282-7
10.1177/0269881119895520
10.1016/j.biopsych.2014.04.010
10.1177/0269881116675512
10.1124/dmd.109.031138
10.1177/096032718200100408
10.3109/00952990.2016.1170135
10.1038/npp.2011.228
10.1080/02791072.1989.10472149
10.1016/S0378-4347(98)00067-X
10.1038/s41591-022-01744-z
10.1016/0028-3908(90)90001-8
10.1007/s00213-022-06123-7
ContentType Journal Article
Copyright The Author(s), 2022. Published by Cambridge University Press
The Author(s), 2022. Published by Cambridge University Press. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s), 2022. Published by Cambridge University Press
– notice: The Author(s), 2022. Published by Cambridge University Press. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID IKXGN
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88G
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
K9.
M0S
M2M
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PSYQQ
Q9U
7X8
DOI 10.1017/S1092852922000888
DatabaseName Cambridge University Press Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Psychology Database (Alumni)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Psychology Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef

ProQuest One Psychology
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: IKXGN
  name: Cambridge University Press Open Access Journals
  url: http://journals.cambridge.org/action/login
  sourceTypes: Publisher
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2165-6509
EndPage 426
ExternalDocumentID 35811423
10_1017_S1092852922000888
Genre Journal Article
Review
GroupedDBID ---
-E.
.GJ
09C
09E
0E1
0R~
123
29B
36B
53G
5VS
6PF
7X7
8FI
8FJ
AAAZR
AABES
AABWE
AACJH
AAEED
AAGFV
AAKTX
AARAB
AASVR
AAUKB
AAWTL
ABBXD
ABBZL
ABGDZ
ABJNI
ABKKG
ABMYL
ABQTM
ABROB
ABUWG
ABWCF
ABXAU
ABZCX
ABZUI
ACBMC
ACCHT
ACETC
ACGFO
ACGFS
ACIMK
ACQFJ
ACREK
ACUIJ
ACUYZ
ACWGA
ACYZP
ACZBM
ACZUX
ADAZD
ADDNB
ADFEC
ADGEJ
ADKIL
ADOCW
ADOVH
ADOVT
ADVJH
AEBAK
AEBPU
AEHGV
AENCP
AENEX
AENGE
AEPLO
AEYHU
AEYYC
AFFUJ
AFKQG
AFKRA
AFLOS
AFLVW
AFUTZ
AGABE
AGJUD
AGLWM
AGOOT
AHIPN
AHLTW
AHQXX
AHRGI
AIGNW
AIHIV
AIOIP
AISIE
AJCYY
AJPFC
AJQAS
AKZCZ
ALMA_UNASSIGNED_HOLDINGS
ANPSP
AQJOH
ARABE
ARZZG
ATUCA
AUXHV
AYIQA
AZGZS
AZQEC
BBLKV
BCGOX
BENPR
BESQT
BGHMG
BJBOZ
BLZWO
BMAJL
BQFHP
BRIRG
C0O
C1A
C45
CBIIA
CCPQU
CCQAD
CCUQV
CFAFE
CFBFF
CGQII
CHEAL
CJCSC
DC4
DOHLZ
DWQXO
E3Z
EBS
EGQIC
EJD
EMB
EMOBN
F5P
FYUFA
GNUQQ
HG-
HMCUK
HZ~
I.6
I.7
I.9
IH6
IKXGN
IOEEP
IOO
IS6
I~P
JHPGK
JQKCU
JVRFK
KAFGG
KCGVB
KFECR
LHUNA
LW7
M-V
M2M
NIKVX
NZEOI
O9-
OHT
OK1
OVD
P2P
PSYQQ
RCA
ROL
RR0
S6-
S6U
SAAAG
SJN
SV3
SY4
T9M
TEORI
TR2
UKHRP
UT1
UU6
WFFJZ
WXY
ZDLDU
ZJOSE
ZMEZD
ZYDXJ
AATMM
AAXMD
AAYXX
ABVKB
ABVZP
ABXHF
ACDLN
ACRPL
ADNMO
AEMFK
AEMTJ
AFFHD
AFZFC
AGQPQ
AKMAY
CITATION
IPYYG
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PUEGO
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c416t-d08c5e76a64b31ad7ef77e7cb3b28360dea963987092f2a82b5165d1cb194813
IEDL.DBID IKXGN
ISICitedReferencesCount 36
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000844412000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1092-8529
IngestDate Fri Sep 05 12:46:38 EDT 2025
Tue Oct 07 07:24:14 EDT 2025
Thu Sep 11 02:52:50 EDT 2025
Tue Nov 18 22:20:55 EST 2025
Sat Nov 29 01:31:37 EST 2025
Wed Mar 13 05:53:53 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords treatment
anxiety
neuroscience
safety
Psilocybin
psychiatry
depression
adverse events
posttraumatic stress disorder
Language English
License http://creativecommons.org/licenses/by/4.0 This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c416t-d08c5e76a64b31ad7ef77e7cb3b28360dea963987092f2a82b5165d1cb194813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-2500-5671
0000-0002-7918-4636
OpenAccessLink https://www.cambridge.org/core/product/identifier/S1092852922000888/type/journal_article
PMID 35811423
PQID 2847984529
PQPubID 5528237
PageCount 11
ParticipantIDs proquest_miscellaneous_2688086323
proquest_journals_2847984529
pubmed_primary_35811423
crossref_primary_10_1017_S1092852922000888
crossref_citationtrail_10_1017_S1092852922000888
cambridge_journals_10_1017_S1092852922000888
PublicationCentury 2000
PublicationDate 2023-08-01
PublicationDateYYYYMMDD 2023-08-01
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-01
  day: 01
PublicationDecade 2020
PublicationPlace New York, USA
PublicationPlace_xml – name: New York, USA
– name: United States
– name: New York
PublicationTitle CNS spectrums
PublicationTitleAlternate CNS Spectr
PublicationYear 2023
Publisher Cambridge University Press
Publisher_xml – name: Cambridge University Press
References 2010; 11
2015; 78
2017; 7
2018; 242
2017; 8
2011; 879
2012; 165
2015; 38
2019; 51
2004; 29
2020; 284
2017; 49
2000; 43
1958; 14
2017; 43
2016; 30
2014; 24
2008; 105
2020; 167
2013; 8
2014; 130
2022; 28
2021; 1164
2012; 72
2018; 9
2021; 78
1982; 1
2019; 64
2002; 43
2011; 65
1975; 1
1997; 16
2020; 177
2011; 68
2020; 45
2008; 22
2011; 25
2008; 62
2010; 5
2021; 41
2014; 11
2020; 218
2018; 37
2019; 197
2018; 142
2018; 29
2017; 20
1959; 42
2010; 38
1989; 1
1989; 21
2002; 30
2002; 7
2013; 228
1999; 20
2021; 384
2020; 34
2016; 126
1962; 11
2012; 37
2014; 231
2018; 23
2007; 53
2022; 239
2012; 109
2004; 99
2021; 16
2021; 10
1997; 72
2021; 12
2021; 11
2015; 29
2013; 33
2017; 14
1998; 709
2019; 44
1990; 29
2015; 20
2017; 56
2018; 235
1998; 30
2016; 26
1998; 9
Eivindvik (S1092852922000888_r17) 1989; 1
S1092852922000888_r48
S1092852922000888_r49
S1092852922000888_r46
S1092852922000888_r47
S1092852922000888_r44
S1092852922000888_r88
S1092852922000888_r45
S1092852922000888_r89
S1092852922000888_r42
S1092852922000888_r86
S1092852922000888_r87
S1092852922000888_r43
S1092852922000888_r40
S1092852922000888_r84
S1092852922000888_r41
S1092852922000888_r85
S1092852922000888_r82
S1092852922000888_r83
S1092852922000888_r80
S1092852922000888_r81
Aghajanian (S1092852922000888_r29) 1975; 1
S1092852922000888_r19
S1092852922000888_r18
S1092852922000888_r59
S1092852922000888_r15
S1092852922000888_r16
S1092852922000888_r57
S1092852922000888_r13
S1092852922000888_r58
S1092852922000888_r14
S1092852922000888_r11
S1092852922000888_r55
S1092852922000888_r56
S1092852922000888_r12
S1092852922000888_r53
S1092852922000888_r54
S1092852922000888_r10
S1092852922000888_r51
S1092852922000888_r52
S1092852922000888_r93
S1092852922000888_r50
S1092852922000888_r94
S1092852922000888_r91
S1092852922000888_r90
S1092852922000888_r28
S1092852922000888_r26
S1092852922000888_r27
S1092852922000888_r68
S1092852922000888_r24
S1092852922000888_r69
S1092852922000888_r25
S1092852922000888_r22
S1092852922000888_r66
S1092852922000888_r23
S1092852922000888_r67
S1092852922000888_r64
S1092852922000888_r20
S1092852922000888_r65
S1092852922000888_r21
S1092852922000888_r62
S1092852922000888_r63
S1092852922000888_r60
S1092852922000888_r61
S1092852922000888_r3
S1092852922000888_r2
S1092852922000888_r5
S1092852922000888_r4
S1092852922000888_r7
S1092852922000888_r6
S1092852922000888_r9
S1092852922000888_r8
S1092852922000888_r39
S1092852922000888_r1
S1092852922000888_r37
S1092852922000888_r38
S1092852922000888_r35
S1092852922000888_r79
S1092852922000888_r36
S1092852922000888_r77
Dimsdale (S1092852922000888_r92) 2021
S1092852922000888_r33
S1092852922000888_r34
S1092852922000888_r78
S1092852922000888_r31
S1092852922000888_r75
S1092852922000888_r76
S1092852922000888_r32
S1092852922000888_r73
S1092852922000888_r30
S1092852922000888_r74
S1092852922000888_r71
S1092852922000888_r72
S1092852922000888_r70
References_xml – volume: 78
  start-page: 481
  issue: 5
  year: 2021
  end-page: 489
  article-title: Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial
  publication-title: JAMA Psychiatry.
– volume: 72
  start-page: 175
  issue: 3
  year: 1997
  end-page: 184
  article-title: Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man
  publication-title: Pharm Acta Helv.
– volume: 30
  start-page: 331
  issue: 2
  year: 2002
  end-page: 339
  article-title: Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man
  publication-title: J Pharm Biomed Anal.
– volume: 42
  start-page: 1557
  issue: 5
  year: 1959
  end-page: 1572
  article-title: Psilocybin und psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen
  publication-title: Helvetica Chimica Acta.
– volume: 26
  start-page: 1327
  issue: 8
  year: 2016
  end-page: 1337
  article-title: Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
  publication-title: Eur Neuropsychopharmacol.
– volume: 33
  start-page: 15171
  issue: 38
  year: 2013
  end-page: 15183
  article-title: Broadband cortical desynchronization underlies the human psychedelic state
  publication-title: J Neurosci.
– volume: 20
  start-page: 311
  issue: 3
  year: 2015
  end-page: 319
  article-title: Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
  publication-title: Mol Psychiatry
– volume: 43
  start-page: 4701
  issue: 24
  year: 2000
  end-page: 4710
  article-title: Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
  publication-title: J Med Chem.
– volume: 29
  start-page: 2081
  issue: 11
  year: 2004
  end-page: 2087
  article-title: Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients
  publication-title: Neuropsychopharmacology.
– volume: 29
  start-page: 530
  issue: 6
  year: 2018
  end-page: 536
  article-title: Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats
  publication-title: Behav Pharmacol.
– volume: 1
  start-page: 417
  issue: 4
  year: 1982
  end-page: 424
  article-title: The problem of psilocybin mushroom abuse
  publication-title: Hum Toxicol.
– volume: 29
  start-page: 289
  issue: 3
  year: 2015
  end-page: 299
  article-title: Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
  publication-title: J Psychopharmacol.
– volume: 177
  start-page: 391
  issue: 5
  year: 2020
  end-page: 410
  article-title: Psychedelics and psychedelic-assisted psychotherapy
  publication-title: Am J Psychiatry.
– volume: 43
  start-page: 28
  issue: Suppl 2
  year: 2002
  end-page: 31
  article-title: Psychostimulants and epilepsy
  publication-title: Epilepsia.
– volume: 1164
  start-page: 122486
  year: 2021
  article-title: Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci
– volume: 7
  start-page: 357
  issue: 4
  year: 2002
  end-page: 364
  article-title: The pharmacology of psilocybin
  publication-title: Addict Biol.
– volume: 72
  start-page: 898
  issue: 11
  year: 2012
  end-page: 906
  article-title: Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors
  publication-title: Biol Psychiatry.
– volume: 9
  start-page: 561
  issue: 7
  year: 1998
  end-page: 566
  article-title: Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans
  publication-title: Behav Pharmacol.
– volume: 30
  start-page: 419
  issue: 4
  year: 1998
  end-page: 426
  article-title: Dr. Leary’s Concord Prison Experiment: a 34-year follow-up study
  publication-title: J Psychoactive Drugs.
– volume: 49
  start-page: 84
  issue: 1
  year: 2017
  end-page: 91
  article-title: Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
  publication-title: Drug Metab Rev.
– volume: 231
  start-page: 4135
  issue: 21
  year: 2014
  end-page: 4144
  article-title: Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes
  publication-title: Psychopharmacology
– volume: 11
  start-page: 642
  issue: 9
  year: 2010
  end-page: 651
  article-title: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
  publication-title: Nat Rev Neurosci.
– volume: 228
  start-page: 481
  issue: 4
  year: 2013
  end-page: 491
  article-title: Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
  publication-title: Exp Brain Res.
– volume: 25
  start-page: 1434
  issue: 11
  year: 2011
  end-page: 1452
  article-title: Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
  publication-title: J Psychopharmacol.
– volume: 142
  start-page: 143
  year: 2018
  end-page: 166
  article-title: The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act
  publication-title: Neuropharmacology.
– volume: 14
  start-page: 397
  issue: 11
  year: 1958
  end-page: 399
  article-title: Elucidation of the structure and the synthesis of psilocybin
  publication-title: Experientia.
– volume: 30
  start-page: 1181
  issue: 12
  year: 2016
  end-page: 1197
  article-title: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
  publication-title: J Psychopharmacol.
– volume: 45
  start-page: 1316
  issue: 8
  year: 2020
  end-page: 1322
  article-title: Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
  publication-title: Neuropsychopharmacology.
– volume: 78
  start-page: 572
  issue: 8
  year: 2015
  end-page: 581
  article-title: Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers
  publication-title: Biol Psychiatry.
– volume: 165
  start-page: 1046
  issue: 4b
  year: 2012
  end-page: 1057
  article-title: Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects
  publication-title: Br J Pharmacol
– volume: 105
  start-page: 1079
  issue: 3
  year: 2008
  end-page: 1084
  article-title: Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo
  publication-title: Proc Natl Acad Sci U S A
– volume: 22
  start-page: 621
  issue: 6
  year: 2008
  end-page: 632
  article-title: Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
  publication-title: J Psychopharmacol.
– volume: 34
  start-page: 167
  issue: 2
  year: 2020
  end-page: 180
  article-title: Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
  publication-title: J Psychopharmacol.
– volume: 24
  start-page: 342
  issue: 3
  year: 2014
  end-page: 356
  article-title: Psilocybin - summary of knowledge and new perspectives
  publication-title: Eur Neuropsychopharmacol.
– volume: 28
  start-page: 844
  issue: 4
  year: 2022
  end-page: 851
  article-title: Increased global integration in the brain after psilocybin therapy for depression
  publication-title: Nat Med.
– volume: 284
  start-page: 112749
  year: 2020
  article-title: The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis
  publication-title: Psychiatry Res.
– volume: 14
  start-page: 734
  issue: 3
  year: 2017
  end-page: 740
  article-title: Potential therapeutic effects of psilocybin
  publication-title: Neurotherapeutics.
– volume: 16
  start-page: 357
  issue: 5
  year: 1997
  end-page: 372
  article-title: Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis
  publication-title: Neuropsychopharmacology.
– volume: 1
  start-page: 295
  issue: 5
  year: 1989
  end-page: 302
  article-title: Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon
  publication-title: Acta Pharm Nord.
– volume: 11
  start-page: 20140873
  issue: 101
  year: 2014
  article-title: Homological scaffolds of brain functional networks
  publication-title: J R Soc Interface.
– volume: 197
  start-page: 83
  year: 2019
  end-page: 102
  article-title: Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function
  publication-title: Pharmacol Ther.
– volume: 11
  start-page: 506
  issue: 1
  year: 2021
  article-title: Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity
  publication-title: Transl Psychiatry.
– volume: 30
  start-page: 1165
  issue: 12
  year: 2016
  end-page: 1180
  article-title: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
  publication-title: J Psychopharmacol.
– volume: 65
  start-page: 121
  issue: 2
  year: 2011
  end-page: 128
  article-title: A prehistoric mural in spain depicting neurotropic psilocybe mushrooms?
  publication-title: Econ Bot
– volume: 38
  start-page: 386
  issue: 3
  year: 2010
  end-page: 395
  article-title: Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases
  publication-title: Drug Metab Dispos.
– volume: 11
  start-page: 261
  year: 1962
  end-page: 269
  article-title: The fate of psilocin in the rat
  publication-title: Biochem Pharmacol.
– volume: 53
  start-page: 439
  issue: 3
  year: 2007
  end-page: 452
  article-title: Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior
  publication-title: Neuron.
– volume: 12
  start-page: 640241
  year: 2021
  article-title: Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property
  publication-title: Front Pharmacol.
– volume: 1
  start-page: 619
  issue: 6
  year: 1975
  end-page: 629
  article-title: Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors
  publication-title: Psychopharmacol Commun.
– volume: 43
  start-page: 55
  issue: 1
  year: 2017
  end-page: 60
  article-title: Long-term follow-up of psilocybin-facilitated smoking cessation
  publication-title: Am J Drug Alcohol Abuse.
– volume: 20
  start-page: 747
  issue: 9
  year: 2017
  end-page: 757
  article-title: Effect of psilocybin on empathy and moral decision-making
  publication-title: Int J Neuropsychopharmacol.
– volume: 44
  start-page: 1328
  issue: 7
  year: 2019
  end-page: 1334
  article-title: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
  publication-title: Neuropsychopharmacology.
– volume: 242
  start-page: 25
  year: 2018
  end-page: 67
  article-title: The renaissance in psychedelic research: What do preclinical models have to offer
  publication-title: Prog Brain Res.
– volume: 51
  start-page: 174
  issue: 2
  year: 2019
  end-page: 188
  article-title: Psychedelic-assisted group therapy: a systematic review
  publication-title: J Psychoactive Drugs.
– volume: 218
  start-page: 116980
  year: 2020
  article-title: Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
  publication-title: Neuroimage.
– volume: 99
  start-page: 686
  issue: 6
  year: 2004
  end-page: 696
  article-title: Comparison of acute lethal toxicity of commonly abused psychoactive substances
  publication-title: Addiction.
– volume: 384
  start-page: 1402
  issue: 15
  year: 2021
  end-page: 1411
  article-title: Trial of psilocybin versus escitalopram for depression
  publication-title: N Engl J Med
– volume: 142
  start-page: 263
  year: 2018
  end-page: 269
  article-title: Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
  publication-title: Neuropharmacology.
– volume: 10
  start-page: e62878
  year: 2021
  article-title: Self-blinding citizen science to explore psychedelic microdosing
  publication-title: Elife
– volume: 38
  start-page: 134
  issue: 1
  year: 2015
  end-page: 138
  article-title: Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats
  publication-title: Biol Pharm Bull.
– volume: 62
  start-page: 404
  issue: 3
  year: 2008
  end-page: 412
  article-title: Hallucinogenic mushrooms in Mexico: an overview
  publication-title: Econ Bot.
– volume: 126
  start-page: 74
  issue: Pt 1
  year: 2016
  end-page: 88
  article-title: Neuropharmacology of N,N-dimethyltryptamine
  publication-title: Brain Res Bull.
– volume: 64
  start-page: 1266
  issue: 4
  year: 2019
  end-page: 1270
  article-title: Unpredictable behavior under the influence of “magic mushrooms”: a case report and review of the literature
  publication-title: J Forensic Sci.
– volume: 8
  start-page: e63972
  issue: 8
  year: 2013
  article-title: Psychedelics and mental health: a population study
  publication-title: PLoS One.
– volume: 242
  start-page: 1
  year: 2018
  end-page: 23
  article-title: An introduction to psychedelic neuroscience
  publication-title: Prog Brain Res.
– volume: 9
  start-page: 2438
  issue: 10
  year: 2018
  end-page: 2447
  article-title: DARK classics in chemical neuroscience: psilocybin
  publication-title: ACS Chem Neurosci.
– volume: 879
  start-page: 2669
  issue: 25
  year: 2011
  end-page: 2672
  article-title: Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis
  publication-title: J Chromatogr B Analyt Technol Biomed Life Sci.
– volume: 12
  start-page: 727117
  year: 2021
  article-title: Psychedelics and other psychoplastogens for treating mental illness
  publication-title: Front Psychiatry.
– volume: 709
  start-page: 255
  issue: 2
  year: 1998
  end-page: 263
  article-title: Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid–liquid extraction with automated on-line solid-phase extraction
  publication-title: J Chromatogr B Biomed Sci Appl.
– volume: 56
  start-page: 1543
  issue: 12
  year: 2017
  end-page: 1554
  article-title: Pharmacokinetics of escalating doses of oral psilocybin in healthy adults
  publication-title: Clin Pharmacokinet.
– volume: 235
  start-page: 399
  issue: 2
  year: 2018
  end-page: 408
  article-title: Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
  publication-title: Psychopharmacology (Berl).
– volume: 167
  start-page: 107933
  year: 2020
  article-title: Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
  publication-title: Neuropharmacology.
– volume: 5
  start-page: e9019
  issue: 2
  year: 2010
  article-title: Psychedelics and the human receptorome
  publication-title: PLoS One
– volume: 239
  start-page: 1989
  year: 2022
  end-page: 2010
  article-title: Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
  publication-title: Psychopharmacology (Berl)
– volume: 41
  start-page: 891
  issue: 5
  year: 2021
  end-page: 900
  article-title: Hallucinogens in mental health: preclinical and clinical studies on LSD, Psilocybin, MDMA, and Ketamine
  publication-title: J Neurosci.
– volume: 21
  start-page: 123
  issue: 1
  year: 1989
  end-page: 128
  article-title: Shamans, sacraments, and psychiatrists
  publication-title: J Psychoactive Drugs.
– volume: 20
  start-page: 424
  issue: 5
  year: 1999
  end-page: 433
  article-title: 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [11C]raclopride
  publication-title: Neuropsychopharmacology.
– volume: 9
  start-page: 3897
  issue: 17
  year: 1998
  end-page: 3902
  article-title: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
  publication-title: Neuroreport.
– volume: 7
  start-page: 13187
  issue: 1
  year: 2017
  article-title: Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
  publication-title: Sci Rep.
– volume: 20
  start-page: 565
  issue: 6
  year: 1999
  end-page: 581
  article-title: Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG
  publication-title: Neuropsychopharmacology.
– volume: 37
  start-page: 268
  issue: 3–4
  year: 2018
  end-page: 278
  article-title: Hallucinogenpersisting perception disorder: a literature review and three case reports
  publication-title: J Addict Dis.
– volume: 23
  start-page: 3170
  issue: 11
  year: 2018
  end-page: 3182
  article-title: Psychedelics promote structural and functional neural plasticity
  publication-title: Cell Rep.
– volume: 109
  start-page: 2138
  issue: 6
  year: 2012
  end-page: 2143
  article-title: Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
  publication-title: Proc Natl Acad Sci U S A.
– volume: 29
  start-page: 193
  issue: 3
  year: 1990
  end-page: 198
  article-title: Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
  publication-title: Neuropharmacology.
– volume: 130
  start-page: 181
  issue: 3
  year: 2014
  end-page: 192
  article-title: Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis
  publication-title: Acta Psychiatr Scand
– volume: 68
  start-page: 71
  issue: 1
  year: 2011
  end-page: 78
  article-title: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer
  publication-title: Arch Gen Psychiatry.
– volume: 37
  start-page: 630
  issue: 3
  year: 2012
  end-page: 640
  article-title: Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers
  publication-title: Neuropsychopharmacology.
– volume: 16
  start-page: 26331055211033847
  year: 2021
  article-title: Engineering safer psychedelics for treating addiction
  publication-title: Neurosci Insights.
– volume: 8
  start-page: 240
  year: 2017
  article-title: The “endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review
  publication-title: Front Psychiatry.
– ident: S1092852922000888_r2
  doi: 10.1007/s12231-011-9152-5
– ident: S1092852922000888_r41
  doi: 10.1248/bpb.b14-00315
– ident: S1092852922000888_r56
  doi: 10.1038/mp.2014.24
– ident: S1092852922000888_r31
  doi: 10.1523/JNEUROSCI.1659-20.2020
– ident: S1092852922000888_r61
  doi: 10.1111/j.1360-0443.2004.00744.x
– ident: S1092852922000888_r53
  doi: 10.1098/rsif.2014.0873
– ident: S1092852922000888_r75
  doi: 10.1038/s41386-020-0694-z
– ident: S1092852922000888_r90
  doi: 10.1177/0269881108094300
– ident: S1092852922000888_r65
  doi: 10.1046/j.1528-1157.2002.043s2028.x
– ident: S1092852922000888_r74
  doi: 10.1097/FBP.0000000000000394
– ident: S1092852922000888_r27
  doi: 10.1371/journal.pone.0009019
– ident: S1092852922000888_r47
  doi: 10.1016/S0893-133X(96)00246-1
– ident: S1092852922000888_r82
  doi: 10.1056/NEJMoa2032994
– ident: S1092852922000888_r70
  doi: 10.1111/1556-4029.13982
– ident: S1092852922000888_r23
  doi: 10.1038/s41386-019-0324-9
– ident: S1092852922000888_r72
  doi: 10.1021/acschemneuro.9b00493
– ident: S1092852922000888_r73
  doi: 10.3389/fphar.2021.640241
– volume: 1
  start-page: 295
  year: 1989
  ident: S1092852922000888_r17
  article-title: Handling of psilocybin and psilocin by everted sacs of rat jejunum and colon
  publication-title: Acta Pharm Nord.
– ident: S1092852922000888_r88
  doi: 10.7554/eLife.62878
– ident: S1092852922000888_r5
  doi: 10.1176/appi.ajp.2019.19010035
– ident: S1092852922000888_r49
  doi: 10.1523/JNEUROSCI.2063-13.2013
– ident: S1092852922000888_r79
  doi: 10.1001/jamapsychiatry.2020.3285
– ident: S1092852922000888_r38
  doi: 10.1177/26331055211033847
– ident: S1092852922000888_r26
  doi: 10.1021/jm000339w
– ident: S1092852922000888_r16
  doi: 10.1016/j.jchromb.2020.122486
– ident: S1092852922000888_r68
  doi: 10.1371/journal.pone.0063972
– ident: S1092852922000888_r32
  doi: 10.1097/00001756-199812010-00024
– ident: S1092852922000888_r63
  doi: 10.1097/00008877-199811000-00011
– ident: S1092852922000888_r71
  doi: 10.1016/bs.pbr.2018.08.003
– ident: S1092852922000888_r37
  doi: 10.1016/j.celrep.2018.05.022
– ident: S1092852922000888_r39
  doi: 10.1038/sj.npp.1300505
– ident: S1092852922000888_r54
  doi: 10.1016/j.neuroimage.2020.116980
– ident: S1092852922000888_r85
  doi: 10.1080/02791072.1998.10399715
– ident: S1092852922000888_r83
  doi: 10.1007/s00213-017-4771-x
– volume: 1
  start-page: 619
  year: 1975
  ident: S1092852922000888_r29
  article-title: Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors
  publication-title: Psychopharmacol Commun.
– ident: S1092852922000888_r80
  doi: 10.1111/acps.12275
– ident: S1092852922000888_r6
  doi: 10.1080/02791072.2019.1593559
– ident: S1092852922000888_r7
– ident: S1092852922000888_r44
  doi: 10.1073/pnas.0708862105
– ident: S1092852922000888_r76
  doi: 10.1001/archgenpsychiatry.2010.116
– ident: S1092852922000888_r20
  doi: 10.1016/0006-2952(62)90050-3
– ident: S1092852922000888_r33
  doi: 10.1016/j.biopsych.2012.04.005
– ident: S1092852922000888_r48
  doi: 10.1016/S0893-133X(98)00089-X
– ident: S1092852922000888_r46
  doi: 10.1016/j.pharmthera.2018.11.010
– ident: S1092852922000888_r94
  doi: 10.3389/fpsyt.2021.727117
– ident: S1092852922000888_r43
  doi: 10.1016/j.neuron.2007.01.008
– ident: S1092852922000888_r45
  doi: 10.1007/s00221-013-3579-0
– ident: S1092852922000888_r62
– volume-title: Dark Persuasion: A History of Brainwashing from Pavlov to Social Media
  year: 2021
  ident: S1092852922000888_r92
– ident: S1092852922000888_r1
  doi: 10.1021/acschemneuro.8b00186
– ident: S1092852922000888_r66
– ident: S1092852922000888_r57
  doi: 10.1016/j.neuropharm.2017.12.041
– ident: S1092852922000888_r4
  doi: 10.1007/s13311-017-0542-y
– ident: S1092852922000888_r42
  doi: 10.1016/S0893-133X(98)00108-0
– ident: S1092852922000888_r69
  doi: 10.3389/fpsyt.2017.00240
– ident: S1092852922000888_r50
  doi: 10.1038/s41398-021-01603-4
– ident: S1092852922000888_r35
  doi: 10.1016/j.euroneuro.2013.12.006
– ident: S1092852922000888_r3
  doi: 10.1007/s12231-008-9033-8
– ident: S1092852922000888_r19
  doi: 10.1080/03602532.2016.1278228
– ident: S1092852922000888_r25
  doi: 10.1016/j.euroneuro.2016.05.001
– ident: S1092852922000888_r89
  doi: 10.1093/ijnp/pyx047
– ident: S1092852922000888_r67
  doi: 10.1080/10550887.2019.1673655
– ident: S1092852922000888_r52
  doi: 10.1073/pnas.1119598109
– ident: S1092852922000888_r12
  doi: 10.1016/S0031-6865(97)00014-9
– ident: S1092852922000888_r81
  doi: 10.1016/j.psychres.2020.112749
– ident: S1092852922000888_r14
  doi: 10.1016/S0731-7085(02)00278-9
– ident: S1092852922000888_r40
  doi: 10.1111/j.1476-5381.2011.01516.x
– ident: S1092852922000888_r10
  doi: 10.1002/hlca.19590420518
– ident: S1092852922000888_r87
  doi: 10.1177/0269881114565144
– ident: S1092852922000888_r51
  doi: 10.1016/bs.pbr.2018.09.013
– ident: S1092852922000888_r21
  doi: 10.1016/j.jchromb.2011.07.003
– ident: S1092852922000888_r30
  doi: 10.1038/nrn2884
– ident: S1092852922000888_r9
  doi: 10.1016/j.brainresbull.2016.04.016
– ident: S1092852922000888_r36
  doi: 10.1016/j.neuropharm.2019.107933
– ident: S1092852922000888_r18
  doi: 10.1080/1355621021000005937
– ident: S1092852922000888_r28
  doi: 10.1007/s00213-014-3557-7
– ident: S1092852922000888_r91
  doi: 10.1177/0269881110382466
– ident: S1092852922000888_r8
  doi: 10.1016/j.neuropharm.2018.05.012
– ident: S1092852922000888_r15
  doi: 10.1007/s40262-017-0540-6
– ident: S1092852922000888_r11
  doi: 10.1007/BF02160424
– ident: S1092852922000888_r78
  doi: 10.1177/0269881116675513
– ident: S1092852922000888_r55
  doi: 10.1038/s41598-017-13282-7
– ident: S1092852922000888_r58
  doi: 10.1177/0269881119895520
– ident: S1092852922000888_r59
  doi: 10.1016/j.biopsych.2014.04.010
– ident: S1092852922000888_r77
  doi: 10.1177/0269881116675512
– ident: S1092852922000888_r22
  doi: 10.1124/dmd.109.031138
– ident: S1092852922000888_r64
  doi: 10.1177/096032718200100408
– ident: S1092852922000888_r86
  doi: 10.3109/00952990.2016.1170135
– ident: S1092852922000888_r34
  doi: 10.1038/npp.2011.228
– ident: S1092852922000888_r84
  doi: 10.1080/02791072.1989.10472149
– ident: S1092852922000888_r13
  doi: 10.1016/S0378-4347(98)00067-X
– ident: S1092852922000888_r60
  doi: 10.1038/s41591-022-01744-z
– ident: S1092852922000888_r24
  doi: 10.1016/0028-3908(90)90001-8
– ident: S1092852922000888_r93
  doi: 10.1007/s00213-022-06123-7
SSID ssj0043783
Score 2.5114715
SecondaryResourceType review_article
Snippet Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the...
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the...
Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybin has four metabolites including the pharmacologically...
SourceID proquest
pubmed
crossref
cambridge
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 416
SubjectTerms Drug dosages
Hallucinogens - adverse effects
Hallucinogens - pharmacology
Hallucinogens - therapeutic use
Humans
Mental Disorders - drug therapy
Metabolism
Metabolites
Mushrooms
Oral administration
Pharmacokinetics
Pharmacology
Plasma
Psilocybin - adverse effects
Psilocybin - analogs & derivatives
Psilocybin - pharmacology
Psilocybin - therapeutic use
Psychedelic drugs
Review
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB60injx_ahWWcGTNJj3bryIiMWDlgpFeiv7ChQkqU0q9N-7k6QJIvYiBAKbnWTJPHZ2Z_YbgGtXK5s7IrBC5kjLD4WwIsV8KxCK23asNS_qp7y_0H6fjUbRoNpwy6q0yqVNLAy1SiXukd-iGY0Yhgnvp58WVo3C6GpVQmMdNrBsNso5HdULLt-jrEywj4zWG8plVBMho7ER21w8q8Kw8EqDrfBzjvrD8SwmoN7uf4e-BzuV60keSlnZhzWdHMDWaxVcP4S3QTYxU9vCrJWJuQqkyyYZ-o5wUp5zIWlMJnlGpg3q9aJLMh7r3Nx5oohGXAouF0cw7D0NH5-tquKCJY1jllvKZjLQNOShLzyHK6pjSjWVwhMunvZQmhuFjYyOR27scuaKwAkD5UjhIOqLdwytJE30KRBtKBGaz1Nc-HGMbpEwQmtWOyLwpNJt6Na_e1ypTTYuU87o-Bd32mAvOTKWFXg51tD4WEVyU5NMS-SOVZ07S9Y1o2n41oar-rFRP4yp8ESnc9MnNAaQhZ7rteGkFI_6awgt5xh39Wz1y89hG2vYl1mFHWjls7m-gE35lU-y2WUh0d-22vik
  priority: 102
  providerName: ProQuest
Title Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
URI https://www.cambridge.org/core/product/identifier/S1092852922000888/type/journal_article
https://www.ncbi.nlm.nih.gov/pubmed/35811423
https://www.proquest.com/docview/2847984529
https://www.proquest.com/docview/2688086323
Volume 28
WOSCitedRecordID wos000844412000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: 7X7
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: BENPR
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Psychology Database
  customDbUrl:
  eissn: 2165-6509
  dateEnd: 20241213
  omitProxy: false
  ssIdentifier: ssj0043783
  issn: 1092-8529
  databaseCode: M2M
  dateStart: 20120601
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/psychology
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swED_aZoy-rN1Xm60NGuxp1MSWPyTvbR1tN9aEbCvDb0ZfhsBwQuwW8t_vZNlOt9JCHwbGBtmSrZN0d_Ld_Q7gPTXaF4GMvYQHyosSKb1U88iLpRa-Xxgjmvwpvy7ZdMqzLJ1tQdbFwli3yh7joLHkN_nRlg7-dDzXzofGrMY_Az-lPKYptdEmdiNnf1qO2yHIW8JvwwA1GIpLdvD1W3Yx7bh0FDLunO9T5AjYSmfxtHDS_7Z8G3fhb_l1j1LaCKfzvf_XrX141iqs5JMreQ5bpnwBTyetSf4lfJ9VcxSIa9xhEzwafMyNC_VHIoiLjiGLgszriiw3WNnrE1KJwtR4FaUmxqJZCLV-BVfnZ1efv3htngZPoTpXe9rnKjYsEUkkw0BoZgrGDFMylNTGiGgjcJmnyBlSWlDBqYyDJNaBkoHFiglfw065KM0hEIM1LaBfqIWMisIqUxKnOu6RZBwqbYZw0lMxb0lS5c5RjeV3SDcEvxurXLWQ5zbzxu-Hqnzoqywd3sdDDx91E2DzNVbep9zas4fwrr-Ni9ZaYkRpFtf4TIJskychDYdw4CZO_zYLSBegkvvmcX19C7sU9S_nm3gEO_Xq2hzDE3VTz6vVCLZZxpozH8Hg9Gw6-zFqVwSWTujkD7WwE4Q
linkProvider Cambridge University Press
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3da9RAEB9qleqLX6162uoK9qU0mGw-diOIiLW09HpUOMq9hf0KHEjubFLl_ij_R2fyiUjvrQ9CIJDsbjbZ2d_OZGd-A_COO-urQMdeIgPjRYnWXmpl5MXaKt_PnVN1_pTLsZhM5GyWXmzA7y4WhtwqO0ysgdouDP0jf08wmkraJvy0_OFR1ijaXe1SaDRiceZWv9BkKz-eHuH47nN-_HX65cRrswp4BpWPyrO-NLETiUoiHQbKCpcL4YTRoeYU0WCdQqFEU9xPec6V5DoOktgGRgfEbBJis3fgLsK4IFtPzHr7LgqFbPz5UwQZ7Gi3iUoM1XSRrnEKjZGU52Wgcvh7SbxBz63Xu-NH_9mXegwPW8WafW5mwhPYcMVT2DpvXQe24dtFOceFe6XnBcOj5vEcXL0_MMWaKB62yNm8Ktly4PReHbJS5a7Csyosc8S6ocxqB6a38T7PYLNYFO4FMIc1iXgwtEpHeU5Kn8YpibacjkNj3QgO-9HNWlAos8ahTmT_CMMI_E4AMtNSs1OGkO_rqhz0VZYNL8m6wrudpAy9GcRkBG_72wgutGOkCre4xjIJwrtMQh6O4Hkjjf3TiDgvQGX85frG38D9k-n5OBufTs5ewQOOOmLjP7kLm9XVtduDe-ZnNS-vXteTiUF2yyL5B90rU7E
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Za9wwEB7StIS8NE2PZHM0CrQvJSa2fEgulBKaLglJli2Ekjejy7BQvJvYadmf1n-XGR9rSum-5aFgMNiSLFufZkbWzDcA77izvgp07CUyMF6UaO2lVkZerK3y_dw5VedP-X4pRiN5c5OOV-B3FwtDbpWdTKwFtZ0a-kd-TGI0lbRNeJy3bhHj0-Hn2a1HGaRop7VLp9FA5MLNf-Hyrfx0fopj_Z7z4dfrL2dem2HAM2iIVJ71pYmdSFQS6TBQVrhcCCeMDjWn6AbrFAIUl-V-ynOuJNdxkMQ2MDoglpMQm30CT0WEZgd5DfKrTglEoZCNb3-KAgc73W2oEls1XaRrnMJkJOV86Wkd_lSP_7B5a9033PiPv9oLeN4a3OykmSGbsOKKl7B21boUvIJv43KCCn2uJwXDo-b37F3APzLFmugeNs3ZpCrZrOf6nh-xUuWuwrMqLHPExqHM_DVcP8b7vIHVYlq4bWAOaxIhYWiVjvKcjEGNUxXXeDoOjXUDOFqMdNYKizJrHO1E9hcwBuB3YMhMS9lOmUN-LKvyYVFl1vCVLCu816Gm700PmQEcLm6j0KGdJFW46T2WSVDsyyTk4QC2GmQunkaEegEa6TvLGz-ANURidnk-utiFdY6mY-NWuQer1d2924dn5mc1Ke_e1vOKQfbIiHwArBJcdA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psilocybin+in+neuropsychiatry%3A+a+review+of+its+pharmacology%2C+safety%2C+and+efficacy&rft.jtitle=CNS+spectrums&rft.au=Dodd%2C+Seetal&rft.au=Norman%2C+Trevor+R.&rft.au=Eyre%2C+Harris+A.&rft.au=Stahl%2C+Stephen+M.&rft.date=2023-08-01&rft.pub=Cambridge+University+Press&rft.issn=1092-8529&rft.eissn=2165-6509&rft.volume=28&rft.issue=4&rft.spage=416&rft.epage=426&rft_id=info:doi/10.1017%2FS1092852922000888&rft.externalDocID=10_1017_S1092852922000888
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1092-8529&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1092-8529&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1092-8529&client=summon